Well I guess it is not quite so funny if you are a shareholder but this acquisition – now – rreversed – has destroyed Ince Group (INCE) as a credible investment. I was urged by the company’s PR to tip the stock but, according to some folks, that really would have been a kiss of death and anyhow it was self-destroying – as I predicted – without my endorsement. 

I have no skin in this game, though I wouldn't wish to own shares in Flip Flop's Kavango Resources (KAV). However, as the two men go to war, it is time to grab some beer and popcorn and enjoy from the sidelines. Then, I look at Asimilar's (ASLR) cash crisis, and Red Rock Resources (RRR) where, despite Andrew Bell pulling his usual trick, I hang on. Finally, I take a detailed look at Ince Group (INCE), where I am now 90% vindicated, with the shares crashing to c. 5p. I await an apology from its PR man, who suggested that, at 52p just before Christmas, I was wrong to be such a bear. To watch my next hat eating, go HERE.

If I were a shareholder in corporate advisor, Arden (ARDN), and had, in late April, swapped my stock for shares in legal and accounting firm, Ince Group (INCE), I would be calling my lawyer right now; Ince has only just released a profit warning for the year ended 31 March 2022.

This marriage of two AIM-sewer-listed companies gets dumber and dumber by the day.

When professional services group, Ince (INCE), announced that it was buying its own, subscale, Nomad Arden Partners (ARDN), I suggested this posed such humungous conflicts of interest that it was a duff deal.  Ince, advised by Arden, disagreed. Ho. Ho. Ho.

In today’s podcast, I discuss Christmas cheeses past and present, Bluebird Merchant Ventures (BMV), Guild E-Sports (GILD), Boohoo (BOO), Ince Group (INCE) Supply@ME Capital (SYME) and Eurasia Mining (EUA).

Two days ago Ince (INCE) the provider of legal and other corporate services announced an all share offer for sub scale Nomad Arden (ARDN). I flagged up then that this was a sign of a top of the market and also that there were bound to be conflicts of interest which would make this deal a nightmare not a blessing. Those COIs have cropped up sooner than expected and shares in Ince were suspended yesterday.

I deal with Skinbiotherapeutics (SBTX) first.  Then it is onto Yourgene (YGEN) and its trading statement, Eurasia (EUA) and a two year farce and finally the bid for Arden (ARDN) by Ince Group (INCE) and what to make of it all. I feel uncomfortable for reasons I explain.

“The Quarto Group Inc. (QRT), the illustrated book publisher and distribution group, today announces that it proposes to raise £13.9 million (approximately $18.2 million) in gross proceeds… at 68 pence per new common share by way of an open offer to the company's existing shareholders”. The price compares to a 75.5p prior close… Ince Group (and Arden Partners) take note!...

Legal and professional services group Ince (INCE) has updated that “it has successfully completed the Bookbuild which is now closed”, with CEO Adrian Biles stating “the funds raised will ensure that the group can continue to capitalise on market opportunities, including new lateral hires. The group has recently been joined by a number of very high calibre partners and fee earners and we are on track to deliver outstanding growth. I am very pleased that so many of our existing investors and some new institutional shareholders have supported this fundraise albeit at a significant discount to the market price of the company's shares, which is an unfortunate feature of the current market conditions”. Er!…